Ottobock SE & Co. KGaA, a global MedTech company, has announced the appointment of Dr. Katarzyna Mazur-Hofsaess to its Management Board effective June 22, 2026. She succeeds Stefan Heidenreich, whose regular five-year term on the board has concluded.
Dr. Mazur-Hofsaess brings extensive international experience in medical technology and healthcare. From 2018 to 2025, she served on the Management Board of Fresenius Medical Care and as CEO of its MedTech segment Care Enablement. Prior to that, she was responsible for the EMEA region at Zimmer Biomet, a US-based specialist in joint replacement solutions. Earlier in her career, she held positions at Abbott Diagnostics and Roche Polska. She currently serves as an independent, non-executive Director at Smith & Nephew.
"With Dr. Katarzyna Mazur-Hofsaess, we are gaining a proven expert in international medical technology and healthcare. Her experience in global companies and her medical background will be a valuable addition to our Board," said Professor Hans Georg Nader, Chairman of the Management Board of Ottobock.
Dr. Mazur-Hofsaess is a physician by training, having studied and earned her doctorate at the Medical University of Gdansk. She also completed management studies at the Warsaw School of Economics and the University of Minnesota. She began her professional career at the University Clinical Centre in Gdansk.
Stefan Heidenreich stepped down following the scheduled end of his five-year term. As Deputy Chairman of the Management Board, he played a key role in shaping the company's strategic development, including its transition to a listed company. Ottobock expressed gratitude for his contributions.
This leadership change comes at a pivotal time for Ottobock, which operates in 45 countries with nearly 9,300 employees and around 420 patient care centers worldwide. The company is known for its innovations in prosthetics, neuro-orthotics, and exoskeletons, and holds more than 2,600 patents and patent applications. Dr. Mazur-Hofsaess's appointment is expected to further drive the company's digitalization and growth in the human bionics landscape.
For more information, view the original release on NewMediaWire.
